Healthesystems’ AVP of Advocacy & Compliance explains how regulation has been unable to keep pace with healthcare innovation & technology.
Healthesystems’ AVP of Advocacy & Compliance explains how regulation has been unable to keep pace with healthcare innovation & technology.
More states cover PTSD without physical injuries for first responders, and 24 states allow PTSD patients to use medical marijuana.
A new wave of drugs that suppress CGRP proteins to reduce migraines could be on the horizon.
Drugs to treat opioid dependence could be approved under new clinical endpoints other than reducing opioid use.
Our Chief Medical Officer and VP of Clinical Services comment on matters such as the use of anticonvulsants to treat pain and opioid prescriptions for inpatients.
Phase 2/3 clinical trial results for Korsuva demonstrate pain relief with fewer side effects.
Millennials are more diverse and more open to alternative therapies, medical marijuana, healthcare technology, and dialogue surrounding psychosocial concerns.
A flurry of recent developments continues to bring the medical marijuana debate front and center, including further legalization, a Senate bill, a drug approval, and more.
In a randomized clinical trial of 460 patients, researchers found the treatment to have similar impact on self-rated disability as standard wound dressing.
Visit Healthesystems in booth #914 to see how we explore the conference’s “Cosmic” theme, and for a chance to win a $250 gift card.
The FDA recently approved drugs to treat opioid dependence, migraines, and rheumatoid arthritis.
Among many findings, JAMA reports that 20% of deaths among those aged 25-34 were opioid-related.
Within the last month, laws have passed in Tennessee, Colorado, South Carolina, Oklahoma, and Hawaii.
Global spending on cancer therapies now exceeds $133 billion.
Our Chief Medical Officer and VP of Clinical Services comment on the clinical use of ecstasy and marijuana.
A newly released draft guidance encourages the development of more sustained-release buprenorphine products.
In-depth reports for 16 different states examine medical payments, costs, duration of disability, and more.
Senate Bill 336 passed with a 44-6 vote and is now headed to the House.
Kratom continues to grow in popularity as a drug for pain and opioid withdrawal, despite concerns from the FDA, CDC and DEA.
In a special partner post with WorkCompWire, Healthesystems discusses developments in pain management, specialty drugs, and more.
If approved, Lucemyra (lofexidine) would be the first non-opioid drug approved to treat the symptoms of opioid withdrawal.
Healthesystems’ VP of Clinical Services discusses how workers’ comp is embracing a value-driven approach.
A new study analyzes the characteristics of chronic opioid use claims, while also examining opioid weaning data.
A Florida bill was recently signed into law, and states such as Arizona, Utah, Connecticut, and Oregon may follow suit.
Indiana and Kentucky signed off on formulary bills, while other states continue to make progress on their promised formularies.
Healthesystems’ Chief Medical Officer will present "Can Workers’ Comp Catch Up to the Rest of Healthcare?" at the 2018 IRSG Annual Conference.
Apadaz oral tablets were approved for the short-term management of acute pain, at no more than 14 days of use.
Healthesystems' VP of Clinical Services will co-present Workers' Comp Opioid Use Trends and Effective Population Health Management
The number of opioid-dependent injured workers in the Ohio workers' comp system fell 19% in 2017.
Many states have attempted to implement fee schedules for air ambulances, but courts citing federal regulations have stricken them down.
Forty-one states and over 200 cities and counties claim drug makers deceived patients and doctors regarding opioid safety and addiction risks.
Senna Laxative bottles were found to contain NSAIDs, while 55 lots of compounded drugs face questionable sterility.
A visual depiction of how opioid side effects can cascade across the body.
When taken in excessive doses, the anti-diarrhea drug loperamide can mimic opioid euphoria, and toxicity events and deaths are on the rise.
The passage of opioid action plans in Arizona, Tennessee, and Pennsylvania are the most recent additions to growing statewide efforts to curb the epidemic.
In 2003, gig workers made up less than 5% of the workforce. Today, estimates vary between 8% and 40%, raising questions for comp.
FDA, opioid, opioids, opioid policy, opioid policies, drug development, non-opioid
Machine learning aims to automate parts of claims management.
Despite decreases in prescribing rates, the opioid epidemic claims more lives than ever before, partially due to synthetic formulations.
The Department of Justice’s recent announcement may come to a head with the will of state governments and popular opinion.
By 2020, millennials will make up half the workforce, so how will they impact workers’ comp?
